XGBoost model demonstrated strong performance with AUROC of 0.895 and sensitivity and specificity of 0.805 and 0.829
MONDAY, Aug. 19, 2024 (HealthDay News) — In a diagnostic study, machine learning (ML) can predict autism spectrum disorder (ASD), according to a study published online Aug. 19 in JAMA Network Open.
Shyam Sundar Rajagopalan, Ph.D., from the Karolinska Institutet in Stockholm, and colleagues developed and validated an ML model for predicting ASD using a minimal set of features from background and medical information. A retrospective analysis of the Simons Foundation Powering Autism Research for Knowledge database was conducted, including data from 30,660 participants (15,330 with and 15,330 without ASD). Generalizable ML prediction models were developed using four algorithms: logistic regression, decision tree, random forest, and eXtreme Gradient Boosting (XGBoost).
The researchers found that the XGBoost model demonstrated strong performance, with an area under the receiver operating characteristic curve (AUROC) score of 0.895; sensitivity and specificity of 0.805 and 0.829, respectively; and a positive predictive value of 0.897. The most important predictors were developmental milestones and eating behavior. An AUROC of 0.790 was seen on validation on independent cohorts, indicating good generalizability.
“Early medical information in child care clinics can be used to screen for those with a higher probability of being diagnosed with ASD,” the authors write.
2005 to 2023 Saw More U.S. Women Never Screened for Cervical Cancer
Machine Learning Model IDs Heart Failure With Reduced Ejection Fraction Using Routine Lab Indicators
Addition of CAC to PREVENT-ASCVD Equations May Improve Predictive Utility in Certain Patients
December 2024 to 2025 Saw Significant Increase in Leucovorin Dispensing
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders
Dexrazoxane Offers Lasting Doxorubicin Cardioprotective Effect in Childhood Cancer Survivors
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings
Many With Atypical Alzheimer Disease Do Not Qualify for Anti-Amyloid Therapy